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Abstract
Increasing evidence supports the involvement of microRNAs (miRNAs) in inflammatory and immune processes in prion
neuropathogenesis. MiRNAs are small, non-coding RNA molecules which are emerging as key regulators of numerous cellular
processes. We established miR-146a over-expression in prion-infected mouse brain tissues concurrent with the onset of prion
deposition and appearance of activated microglia. Expression profiling of a variety of central nervous system derived cell-lines
revealed that miR-146a is preferentially expressed in cells of microglial lineage. Prominent up-regulation of miR-146a was
evident in the microglial cell lines BV-2 followingTLR2or TLR4activation and also EOC 13.31 viaTLR2thatreached a maximum
24–48 hourspost-stimulation,concomitantwiththereturn tobasallevelsoftranscriptionofinducedcytokines.Gain-and loss-
of-function studies withmiR-146a revealed a substantial deregulation of inflammatory response pathways in response to TLR2
stimulation. Significant transcriptional alterations in response to miR-146a perturbation included downstream mediators of
the pro-inflammatory transcription factor, nuclear factor-kappa B (NF-kB) and the JAK-STAT signaling pathway. Microarray
analysis also predicts a role for miR-146a regulation of morphological changes in microglial activation states as well as
phagocytic mediators of the oxidative burst such as CYBA and NOS3. Based on our results, we propose a role for miR-146a as a
potent modulator of microglial function by regulating the activation state during prion induced neurodegeneration.
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Introduction
Prion diseases, or Transmissible Spongiform Encephalopathies
(TSEs), belong to a group of progressive neurodegenerative
conditions that affect the nervous system in humans and animals.
They can have a genetic etiology as well as occurring sporadically
without any known risk factors or gene mutations. Uniquely, they
are able to be transmitted in some instances, through foods and
medical products contaminated with infectious prions. Disease
progression is associated with the conversion of a normal cellular
protein (PrP
c) into an abnormal isoform associated with patho-
genesis (PrP
Sc), which in turn can build up in the brain as deposits
in a similar fashion to amyloid in Alzheimer’s diseased brains [1].
As is the case in other neurodegenerative conditions, such as
Alzheimer’s disease, one of the pathological features of disease is
the activation of the brain’s resident immune cells, the microglia,
and the accumulation of astrocytes. In many instances, this feature
can be detected prior to clinical symptoms and other signs of
neurodegeneration, such as spongiosis and neuronal cell death
become apparent [2,3].
Microglia are normally quiescent but when activated they may
undergo morphological changes, proliferation, chemotaxis and
produce numerous cytokines and chemokines involved in
inflammatory and immunomodulatory responses [4–6]. Such an
inflammatory milieu has been recognized in the prion infected
brain for some time; however, whether the activation of this innate
immune response is beneficial or harmful in prion-like pathologies
is still unknown. Increasing evidence suggests that microglial cells
may be multi-functional, playing roles in brain tissue repair and
neurogenesis, as well as in immunity [7].
In prion disease, microglia appear to express low levels of pro-
inflammatory cytokines during chronic neurodegeneration but
may be in a ‘‘primed’’ state [8]. The specific stimuli and signaling
pathways that lead to these modulations of functions, and the
mechanisms by which microglial activation influences chronic
neurodegeneration, are as yet unknown. The contribution of toll-
like receptors (TLRs), a family of proteins that are central players
in the stimulation of innate immune responses, has been
investigated in relation to prion disease progression. Upon
recognition of their ligands, TLRs transduce intracellular signals
via intermediary proteins including MyD88, TIRAP, TRIF, and
TRAM, and signaling molecules such as IRAK4, IRAK1, and
TRAF6. These signals translate to the production of cytokines and
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oxygen intermediates required for the phagocytic process.
Un-methylated CpG DNA, which is an agonist of TLR9
signaling, has been shown to prolong the scrapie incubation period
in mice, suggesting that innate immune activation can interfere
with prion disease progression [9,10]. Subsequently, transgenic
mice with defective TLR4 signaling causing them to be
hyporesponsive to lipopolysaccharide (LPS) were found to exhibit
a significantly accelerated rate of prion disease development in
comparison to their wild-type counterparts [11]. Interestingly, the
anti-prion mechanisms induced by TLR4 signaling appear to be
functional in the CNS rather than the periphery, as the rate of
disease acceleration is similar in mice infected by both intra-
peritoneal and intra-cerebral routes. Pathogenic changes in prion
disease appear to be independent of MyD88, a signaling
intermediate for several TLR family members, as ablation of this
molecule did not lead to changes in the incubation periods, and
neuropathological profiles of scrapie-infected mice [12].
Recent evidence suggests that small RNA molecules (micro-
RNAs) are capable of regulating gene expression post-transcrip-
tionally and play important roles in modulating the response of
immune cells to stimuli [13]. MicroRNAs (miRNAs) are evolution-
ary conserved, non-coding, highly abundant small RNAs approx-
imately 22 nucleotides long [14]. They are able to silence mRNA
expression by sequence specific binding within the 39UTR of
protein-coding mRNA which results in either cleavage of the
message or translational repression [15]. One miRNA in particular,
miR-146a, has been shown to play an important role in the
modulation of the innate-immune response. MiR-146a can directly
down-regulate the production of pro-inflammatory cytokines by
acting as a negative-feedback effector of the inflammatory signaling
pathway initiated by NF-kB [16]. Recent work in our own
laboratory showed the amount of miR-146a in the brain of scrapie
infected mice to be significantly increased in comparison with age-
matched control mice [17]. MiR-146a functionality has been
explored in macrophages but its role in neurodegeneration has not
yet been completely elucidated. We hypothesized that given the
immunomodulatoryrole ascribed tomiR-146ainmacrophages;up-
regulation of miR-146a in scrapie infected brain may reflect a role
in keeping the pro-inflammatory response of microglia to prion
replication and degeneration ‘‘in-check’’.
Materials and Methods
Ethics statement
All procedures involving live animals were approved by the
Canadian Science Centre for Human and Animal Health -
Animal Care Committee (CSCHAH-ACC). All protocols were
designed to minimize animal discomfort. The approval ID for this
study was #H-O8-009.
Biological material
CD-1 mice were inoculated intracerebrally with 20 mlo f1 %
brain homogenate from mice infected with the RML strain of
mouse adapted scrapie. At the onset of clinical symptoms, 6 mice
per sample group were sacrificed and hippocampus or cerebellar
tissue used for RNA extraction. An equal number of age-matched,
mock-infected mice (inoculated with a 1% brain homogenate of
healthy CD-1 mice) were used as controls for each group.
Cell culture
Two murine microglial cell lines were employed in this study,
BV-2 and EOC 13.31 cells. The BV-2 cells were kindly provided
by Dr. Yoon-Seong Kim (Department of Neurology/Neurosci-
ence, Weill Medical College of Cornel University, New York) and
the EOC 13.31 cells were obtained from the American Type
Culture Collection Centre (ATCC). Both cell lines were grown
and maintained in DMEM (ATCC) supplemented with 10% heat-
inactivated FBS (Sigma) in a humidified incubator containing 5%
CO2 at 37uC. However, the EOC 13.31 cells were additionally
supplemented with 20% LADMAC conditioned media. LAD-
MAC conditioned media was made from LADMAC cells
purchased from ATCC that secrete CSF-1 as per manufacturer’s
instructions.
TLR stimulation and neutralization of TLR2
2610
5cells/well were plated onto 24-well plates and incubated
overnight in a humidified incubator containing 5% CO2 at 37uC.
Cells were then stimulated for various time points with various
concentrations of two types of LPS (E. coli 055:B5, Sigma)(E.coli,
serotype EH100 (Ra), Enzo Life Sciences) or mock-treated cells as
negative controls. To check the purity of both LPS stocks and that
signaling was indeed through TLR4, cells were incubated for
30 minutes with various concentrations of purified monoclonal
antibody to mouse (mAb mTLR2) (Invitrogen) followed by
24 hours stimulation with 100 ng/ml LPS. TLR2 stimulation
was performed following incubation of cells in a humidified
incubator containing 5% CO2 at 37uC for 8 hours at which time
they were stimulated with 10
8 cells/ml of heat-killed Listeria
monocytogenes (HKLM) (Invitrogen).
Mir-146a over-expression/knock-down
Over-expression of miR-146a was mimicked using a lipid-based
reverse transfection system (siPORT
TM NeoFX
TM (Ambion))
following manufacturer’s instructions. Briefly, pre-miR
TM (pre-
cursor molecule for our over-expression strategy) miRNA-146a
molecule along with the respective pre-miR
TM miRNA precursor
negative control #1 (Ambion) were diluted in OPTI-MEMH I
medium (Invitrogen) to achieve a final concentration of 30 nM
and then added with an equal volume of diluted siPORT NeoFX
to each well of a 6-well plate. BV2 cells suspended in DMEM
supplemented with 10% heat-inactivated FBS were overlaid in
each well for a final total cell count of 2610
5 cells/well. Cells were
incubated in a humidified incubator containing 5% CO2 at 37uC
for 8 hours at which time they were stimulated with 10
8 HKLM
cells/ml (Invitrogen) for 24 hours.
Knock-down of miR-146a was achieved using the same
transfection agent as previously stated (Ambion). Briefly, anti-
miR
TM (anti-sense miRNA molecule) miRNA-146a molecule along
with the respective anti-miR
TM miRNA negative control (Ambion)
were diluted in OPTI-MEMH I medium to achieve a final
concentration of 50 nM. The remainder of the procedure was
followed the same way as previously stated for the over-expression
studies including stimulation with HKLM. Additional negative
controls included mock-transfected and mock-stimulated cells.
Cytokine quantitation
To determine the levels of interleukin-6 (IL-6) and Granulocyte
Macrophage - Colony Stimulating Factor (GM-CSF) secreted
from the cells, supernatant was collected and a solid phase ELISA
(Quantikine Mouse IL-6 or GM-CSF (R&D Systems)) was
performed according to manufacturer’s instructions.
RNA isolation and miRNA quantitative real time-PCR
(qRT-PCR)
To analyze miRNA expression, total RNA was isolated from
cell culture using the miRVana miRNA Isolation kit (Ambion)
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measured and quantified using the TaqManH miR-146a miRNA
Assays (Applied Biosystems) according to the manufacturer’s
protocol. MiRNA expression was normalized to the U6 snRNA
level which was expressed at high levels with negligible variance
under the experimental conditions used in our study. Fold change
was determined using 2
2DDCt method.
MiRNA microarray
The miRNA microarray was fabricated in-house. Low molec-
ular weight (LMW) RNA (,200 nucleotides in length) was
extracted from the cells passaged 3–4 times. The LMW RNA was
then divided into equal halves, with one half being labeled with
AlexaFluor 555 and the other half with AlexaFluor 647, for self/
self hybridization experiments on the miRNA microarray.
Hybridizations for each cell line were performed in quadruplicate.
The criterion that was used for the inclusion of a miRNA in the
overall repertoire of a cell line was correlation in spot intensity
between the dye spots for a particular miRNA and intensity values
stronger than a minimum arbitrary value of 10.
Generation of amplified (aRNA), labeling and purification
The production of aRNA from total RNA was obtained using
the AminoAllyl MessageAmp
II kit (Ambion) protocol according to
the manufacturer’s instructions. In brief, one round of amplifica-
tion from total RNA samples was performed for each treated and
control sample in order to generate enough target material for a
dual-colour competitive hybridization. 1000 ng of total RNA was
used to make the first cDNA strand. Once aRNA synthesis was
complete, it was purified and split into two samples (,10 mgo f
aRNA per sample) for dye-swapping experiments before vacuum
drying in order to account for dye bias in the experiment. Once
each sample dried, they were resuspended in coupling buffer
(Ambion) and one sample labeled with an Alexa-Fluor 555
carboxylic acid succinimidyl ester dye (Invitrogen, Molecular
Probes) and the other with Alexa-Fluor 647 carboxylic acid
succinimidyl ester dye (Invitrogen, Molecular Probes) each made
up in DMSO. Once the aRNA was labeled, it was purified and
quanitated using a nanodrop spectrophotometer (Agilent technol-
ogies).
Microarray slide hybridization
Each labeled aRNA sample was prepared, fragmented, and
hybridized to an Agilent whole mouse genome 4644K (Agilent)
commercially manufactured array according to Agilent technol-
ogies manufacturer’s instructions for two-color microarray-based
gene expression analysis (version 5.0.1 August 2006) for 4644K
arrays. The arrays were hybridized for a total of 17 hrs at 65uC
with vertical rotation.
Microarray slide washing and scanning
The slides were washed according to Agilent’s manufacturer’s
protocol for 4644K arrays and scanned with the Agilent
Microarray Scanner system with surescan technology (v.6.3) using
the scanner settings for the 4644K array format according to
Agilent technologies manufacturer’s instructions.
Data analysis
The .TIFF images were uploaded into Feature Extraction
Software v9.1 (Agilent technologiesG2567AA), spots were identi-
fied, and the grids constructed using the GE2-v5_91_0806
protocol and the 014868_D_20060807 grid file for ‘‘whole mouse
genome’’ 4644K expression arrays. Background calculations
using spatial and multiplicative detrending and normalization
using linear and lowess were performed by the Feature Extraction
software. The p-value for differential expression was 0.01 and the
resulting gene list was provided as log10 ratios of red (AlexaFlour
647)/green (AlexaFlour 555). Statistical analysis was performed
using statistical analysis of microarrays (SAM) [18]. All microarray
data is MIAME compliant and the raw data has been deposited to
the Gene Expression Omnibus (GEO) under accession numbers:
[GSE17759].
Results
MiR-146a is consistently up-regulated in the brain’s of
prion infected mice
We recently reported that miR-146a is amongst a select group
of miRNAs up-regulated in the whole brains of mice infected with
scrapie [17]. Quantitative real time-PCR (qRT-PCR) analysis
using TaqManH miRNA probes, specific for mouse miR-146a,
revealed that this increase in expression is consistently found in
mice clinically infected with a number of scrapie strains (22A,
RML, and BSE) in comparison to age matched, mock-infected
mice (Table 1). Between a 3- and 16-fold increase in the level of
expression was detected in RNA extracted from whole brain,
hippocampus and cerebellar tissue samples.
MiR-146a functionality has been explored in macrophages but
its role in neurodegeneration has not yet been elucidated [16].
PrP
Sc induces inflammatory responses by the brain’s glial cells
(astrocytes and microglia) by activating innate immunity pathways.
Given the immunomodulatory role ascribed to miR-146a in
macrophages, we hypothesized that expression in the brain would
likely be enriched in astrocytes and/or microglia. In situ
hybridization to detect miR-146a expression proved inconclusive
in confirming this (data not shown). We therefore profiled RNA
from multiple brain-derived cell lines of both mouse and human
origin to conditionally determine the expression profiles of a
number of miRNAs, including miR-146a. These cell lines
included neuronal subtypes (N2A, NB41A3, SKNFI, IMR32),
microglial subtypes (EOC 13.31, EOC 20) and astrocyte subtypes
(C8D30, C8S, C8D1A). Cultured cells were passaged 3–4 times
prior to the extraction of low molecular weight (LMW) RNA
(,200 nucleotides in length), which was then labeled and
hybridized to a miRNA microarray [19]. A representative
hierarchical cluster plot to visualize this data is provided in
Figure 1. Small clusters of neuronal-, astrocyte- and microglia-
enriched miRNAs are also apparent. The neuronal cluster
included miR-124, a miRNA that is especially abundant in
neurons affirming the specificity of the methodology [20–22]. The
microglial cell-line enriched cluster contained 20 miRNAs
including miR-146a and a number of other miRNAs reportedly
involved in inflammation, such as miR-155, miR-221 [23] and
miR-147, a microRNA that is induced upon Toll-like receptor
(TLR) stimulation and regulates murine macrophage inflamma-
tory responses [24].
The microglial surface receptor, TLR2, is significantly
induced in the brain’s of prion infected mice
MiR-146a is reported to be up-regulated in LPS stimulated
human macrophages, however, the microglial surface receptor
that is engaged leading to activation during prion pathogenesis is
unknown [16]. We used a microarray analysis to determine which
microglial surface receptors are over-expressed in the brains of an
RML scrapie model of prion disease and may therefore play a
pertinent role in activation. Brain tissue from the hippocampal and
cerebellar regions of scrapie infected mice at clinical stages of
Dysregulation of miR-146a and Microglial Function
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TLR2 gene (the most abundant TLR gene based on microarray
probe intensity) as well as genes coding for the receptor accessory
molecules LY96 and CD14 (Table 2). The only other TLRs we
determined to be significantly up-regulated were TLR1 and
TLR7. However, the mRNAs of other TLRs, including TLR4,
were barely detectable in our study and so we could not determine
whether there was an increase in expression of these receptors in
the infected animals. Other receptors including Fc (FCGR1 and
FCGR3) and complement receptors (ITGAM and ITGAX), as
well as TREM2 a myeloid specific receptor triggered by amyloid
to promote active phagocytosis, were also found to be over-
expressed. Scavenger receptors (SCARB1, SCARB2 and AGER),
except for CD68, did not show significant induction.
MiR-146a expression is induced in microglial cell lines by
TLR2- and TLR4-agonists
Previous studies have shown that miR-146a is up-regulated in
LPS stimulated human monocytic cell line THP-1, a cell line that
expresses Fc and C3b receptors and is a common cell culture
model for the study of macrophages [16]. We investigated whether
a similar response was induced by LPS in a microglial-derived line,
BV-2. This line is derived from murine microglial cells that were
immortalized after infection with a v-raf/v-myc recombinant
retrovirus. These cells share numerous properties with macro-
phages with respect to the antigen profile, their phagocytic
capacity and antimicrobial activity [25]. Additionally, like
microglial cells, they form spineous processes and express inwardly
rectifying, but not outwardly rectifying K
+ channels [25]. BV-2
cells were treated with LPS at varying concentrations (between
0.1–100 ng/mL) over a period of 8 hours. MiR-146a levels were
determined by TaqManH qRT-PCR and provided in Figure 2A.
In general, the expression of miR-146a increased upon LPS
stimulation to a maximum of 13-fold at 100 ng/ml. LPS signaling
is mediated by TLR4 since mutations or deletions of the Tlr4 locus
completely abolish LPS-mediated signaling [26,27]. To show that
miR-146a induction is specifically mediated by the LPS/TLR4
signaling pathway we used a second microglial line, EOC 13.31
derived from C3H/Hej mice that has a spontaneous mutation in
the TLR4 gene (Tlr4
Lps-d) making it hyporesponsive to LPS [28].
We also observed significant up-regulation of miR-146a in EOC
13.31 cells which we hypothesized to be likely due to the presence
of a contaminant in the particular LPS preparation in use, an
observation previously reported by others [29]. Stimulation with
an ultrapure LPS preparation did not evoke miR-146a up-
regulation in EOC 13.31 cells confirming this was the most likely
explanation (Figure 2B). Taganov et al (2006) previously showed
that TLR2 stimulation by exposure to peptidoglycan and its
synthetic analog, Pam3CSK4, produced an up-regulation of miR-
146a in human monocytes in contrast to TLR3, TLR7 and TLR9
agonists. To test whether the crude LPS preparation in our
laboratory contained agonists that could stimulate EOC 13.31
TLR2 receptors, we treated the cells with an anti-TLR2 antibody
for 30 minutes prior to treatment with LPS. This treatment, in
turn, prevented the induction of miR-146a in EOC 13.31 cells
stimulated via the crude LPS preparation, but not similarly treated
BV-2 cells (Figure 2C). Treatment with an ultra-pure TLR2
agonist, HKLM, resulted in an induction of miR-146a in both cell
lines (Figure 2D). Given that TLR2 and TLR4 stimulation of
microglial cell lines can lead to an increase in expression of miR-
146a, potentially either one, or both, of these molecules are
involved in the signaling that leads to the up-regulation of this
miRNA in the brain’s of prion infected mice. Nevertheless, the
expression of TLR2 is much greater than TLR4 (below detection
threshold) in the brain’s of mice tested in this study.
Temporal induction of miR-146a expression in microglia
is kinetically distinct to that of TLR2 signaling-induced
cytokines
Agonists to TLR2 and TLR4 induce the rapid expression of
cytokines which return to endogenous levels expeditiously. To
determine whether the induction of miR-146a in BV-2 and EOC
13.31 cells followed a similar path we stimulated with an 100 ng/
ml concentration of the semi-pure LPS preparation and measured
expression relative to mock-treated control cells using TaqManH
qRT-PCR. Agonist treatment uniformly resulted in the significant
induction of miR-146a expression that increased over time to a
maximum at 48 hours post-stimulation, but was still elevated even
at 72 hours post stimulation (Figure 3). This was is in contrast to
the generally rapid induction of cytokine expression following LPS
stimulation. We specifically followed the levels of transcripts
coding for the cytokines, IL-6 and CSF2 (colony stimulating factor
2 or GM-CSF), and tumor necrosis factor (TNF). All three were
found to peak well before 24 hours post-stimulation and had all
returned to basal levels by 48 hours (Figure 3). These data suggest
that induction of miR-146a may be secondary to the initial
response triggered by the TLR agonist. This has been previously
described in macrophages where miR-146a expression was found
to be capable of dampening the immediate innate immune
response mediated by TLR2 and TLR4 [16,30,31].
Transcription of genes involved in protein synthesis,
infection mechanism, immune cell trafficking, oxidative
phosphorylation and cellular movement are modulated
by miR-146a expression in microglia
With the aim of identifying those biological functions under
miR-146a control, we used a functional genomic strategy to
determine the extent of transcriptional changes modulated by
miR-146a expression in the microglial cell line EOC 13.31. This
Table 1. Expression levels of miR-146a in brain tissue of mice infected with mouse-adapted scrapie or BSE as determined by
quantitative RT-PCR (TaqManH qRT-PCR) (relative quantitation was determined using the 2
2DDCt method).
Scrapie strain Mouse strain Tissue
Fold increase (infected vs.
uninfected)
p-value (t-test) (infected vs.
uninfected)
22A VM Whole brain 3.3 9.4610
22
RML CD1 Hippocampus 8.3 3.5610
22
RML CD1 Cerebellum 16.3 6.8610
23
BSE CD1 Cerebellum 10.0 7.6610
22
doi:10.1371/journal.pone.0030832.t001
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anti-miR (complementary to miRNA) and pre-miR (precursor
miRNA or miRNA mimics) being detectable in the cells for much
longer, up to 36 hours post infection, despite the fact that the
transfection rates for both cells were similar (data not shown). This
was likely due to differences in the proliferation rates exhibited by
Figure 1. Hierarchical cluster plot generated from miRNA expression profiling of a repertoire of a variety of CNS cell lineages
(neuronal, microglia, astrocytes). A microglia specific cluster of miRNAs is indicated. Red indicates high levels of miRNA expression, green low
levels and gray indicates expression that was undetected by the microarray used.
doi:10.1371/journal.pone.0030832.g001
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least once during a 24 hour period, EOC 13.31 cells doubled only
every 48 hours. This enabled us to obtain maximal knock-down
and over-expression of miR-146a, whilst allowing the cells to
recover overnight following transfection prior to RNA extraction,
therefore minimizing expression changes that might be due to the
transfection procedure itself. Over-expression was achieved by
transfecting 30 nM of miR-146a mimic (Figure 4A). We
experimentally determined that knock-down of miR-146a in
EOC 13.31 cells was optimal between 16 and 48 hours post-
transfection upon transfection of 50 nM of miR-146a anti-miR
(Figure 4B).
Over-expression of a miR-146a mimic for 24 hours resulted in
significant deregulation of hundreds of genes; 1668 genes had
$1.5-fold alteration of expression (FDR #2%) in comparison to
EOC 13.31 cells transfected with a scrambled control RNA.
Analysis of these data based on enrichment for biological functions
was performed using the Ingenuity Pathway Analysis (IPA) tool,
which revealed a significant number of the deregulated genes to be
involved in cell morphological changes, cell signaling, RNA post-
transcriptional modification and cell cycle regulation. Changes
include the down-regulation of molecules such as ITGA4,
ITGAV, S1004A, CCL17, CDKN1B, VEGFA and ERBB2
involved in cell movement, adhesion and shape change.
Additionally, a broad spectrum of genes involved in antimicrobial
activity were mostly down-regulated including some genes
involved in signaling pathways from TLR and Fcc receptor-
mediated phagocytosis including HCK, LYN, PKCG1, SYK and
ARF6. Complement factor H (CFH) and mannose-binding lectin
serine peptidase 2http://www.genenames.org/data/hgnc_data.
php?hgnc_id=6902 (MASP2), two proteins secreted into the
bloodstream that play roles in the regulation of complement
activation, were also deregulated. CFH and MASP2 are both
involved in antibody-independent phagocytosis and are essential
regulators of complement activation that restrict this innate
defense mechanism to microbial infections. CFH has also been
reported to be a direct target of miR-146a and potentially
important in inflammation in Alzheimer’s disease [32,33].
Another significant group of genes that exhibited down-regulated
expression incorporate those related to the oxidative burst
phenomenon that is at play during phagocytosis. These included
the genes NOS1, NOS2 and NOS3, nitric oxide synthases that are
inducible by TLR stimulation and NOX4, a gene involved in
H2O2 production. Significantly, the genes CYBA and CYBB
proposed to be primary components of the microbicidal oxidase
system of phagocytes, were also down-regulated, as was SOD3.
SOD1, however, was up-regulated in our work. These isozymes
are soluble cytoplasmic proteins responsible for the conversion of
superoxide radicals to molecular oxygen and hydrogen peroxide.
A smaller group of up-regulated genes were identified following
miR-146a over-expression. Ontological analysis determined the
most significant group of 35 genes (p=2.4610
29) to be involved in
RNA post-transcriptional modification. These genes included
TNRC6A and TNRC6B, whose gene products are members of
the trinucleotide repeat containing 6 protein family and function
in post-transcriptional gene silencing through the RNA interfer-
ence (RNAi) and miRNA pathways. They associate with
messenger RNAs and Argonaute proteins in P-bodies.
Substantially fewer genes were dysregulated following transfec-
tion of miR-146a anti-miR and these were for the most part up-
regulated. Ontological analysis revealed a significant number of
these genes to be involved in protein synthesis, infection
mechanisms, immune cell trafficking, oxidative phosphorylation
and cellular movement. Ribosomal proteins were strikingly up-
regulated resulting in a significance score in IPA of
p=1.13610
254, similarly numerous mitochondrial cytochrome
C oxidase subunits involved in oxidative phosphorylation were
also up-regulated. Another interesting up-regulated gene was the
ferritin light chain (FTL) which is involved in the protection of cells
from oxidative stress. The gene DC-SIGN (CD209) was one of
those innate immune related genes that exhibited increased
expression following knock-down of miR-146a. DC-SIGN is a
transmembrane receptor that recognizes numerous evolutionarily
divergent pathogens ranging from parasites to viruses with a large
impact on public health. Interestingly, knock-down of DICER1,
required for miRNA processing has recently been shown to alter
the levels of DC-SIGN in dendritic cells revealing potential
regulation by miRNAs. TANK, a TRAF family member
associated with NF-kB activation, was also up-regulated by miR-
146a knock-down. TANK is activated by TRAF6, and appears to
be part of a NF-kB regulatory loop. Previous studies have shown
that TANK can act both in both positive- and negative-regulation
of NF-kB and interferon pathways by positively regulating IRF3.
It has been previously reported that most translational
repression is accompanied by miRNA-mediated mRNA degrada-
tion, we therefore used this assumption to predict potential direct
targets of miR-146a in this system [34,35]. We determined the
intersection between miRNA targets bioinformatically predicted
by Targetscan 5.1, mRNAs down-regulated following miR-146a
over-expression, and mRNAs up-regulated following miR-146a
knock-down. The results are summarized in Figure 5A and Table 3
provides a list of the genes that were common. A network of the
deregulated genes that are also potential miR-146a direct targets is
provided in Figure 5B. This includes the down-regulation of the
Table 2. Expression levels of microglial cell surface receptors
in hippocampal tissue of RML infected, symptomatic mice as
determined by microarray analysis.
Gene
Fold increase
(infected vs.
uninfected)
p-value (t-test)
(infected vs.
uninfected)
Toll like receptors & co-receptors
TLR2 18.6 0.001
TLR7 5.8 0.034
TLR1 10.9 0.081
LY-96 (MD-2) 4.9 0.023
CD14 16.2 0.013
Scavenger receptors
SCARB1 1.3 0.574
SCARB2 1.0 0.958
CD68 13.8 0.040
AGER 1.1 0.394
Fc receptors
FCGR1 24.5 0.003
FCGR2 4.4 0.047
Complement receptors
ITGAM 6.5 0.003
ITGAX 15.1 0.030
Other microglial receptors
TREM2 13.2 0.018
doi:10.1371/journal.pone.0030832.t002
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following knock-down. The gene IL-1B has previously been
reported to be negatively regulated by miR-146a [30].
Transcription of genes involved in NF-kB, JNK and MAPK
signaling pathways and the expression of inflammatory
mediators are modulated by miR-146a expression in
TLR2 stimulated microglia
We hypothesized that the majority of miR-146a targets that act
as important microglial immune response regulators would likely
only be evident during conditions in which cells were stimulated by
a ligand. To this end we transfected EOC 13.31 cells with miR-
146a anti-miRs or mimics prior to stimulation of TLR2.
Transfected anti-miRs or mimics were stably detected over a
24–48 hour period post transfection; therefore cells were trans-
fected and allowed to recover overnight, thus reducing the
likelihood of differential expression induced by the transfection
process, prior to stimulation. We initially transfected a miR-146a
anti-miR as a means to determine genes whose expression was
potentially relieved, either directly or indirectly, by a reduction in
miR-146a. RNA was extracted at 8 hours and 24 hours following
LPS treatment and the transcriptional response was determined by
microarray analysis in comparison with mock-treated controls.
Indeed, we did find a significant number of up-regulated genes at
8 hours (691 annotated genes), with a smaller number (354
annotated genes) up-regulated at 24 hours post stimulation. As
expected, a great deal of consistency was evident between the two
data sets, 287 of the 354 genes up-regulated at 24 hours were also
up-regulated at 8 hours. Very few genes exhibited significant
down-regulation following this treatment; only 6 at 8 hours post
stimulation, and 2 at 24 hours, both of these two genes were
amongst the 6 genes identified at 8 hours confirming very high
reproducibility of the microarray data. Examination of the
ontologies enriched in this set of up-regulated genes showed genes
Figure 2. MiR-146a induction in microglia. A. LPS at concentrations ranging from 0.1–100 ng/ml was used to stimulate BV-2 cells. After 8 hours,
RNA was collected and TaqManH qRT-PCR was used to determine miR-146a expression relative to PBS treated (unstimulated) control cells. The
experiment was performed in triplicate and the average fold induction is shown. B. EOC 13.31 cells were stimulated with 100 ng/ml semi-pure LPS,
100 ng ultra-pure LPS or PBS alone (unstimulated). RNA was collected after 8 hours and miR-146a expression was measured by TaqManH qRT-PCR.
Fold induction relative to untreated cells is shown. The experiment was performed in triplicate and the average fold change is shown. C. EOC 13.31
cells were incubated with increasing concentrations of an anti-TLR2 antibody for 30 minutes prior to stimulation with 100 ng/ml LPS. MiR-146a
expression relative to mock-treated control cells was measured by TaqManH qRT-PCR. Inhibition of miR-146a expression following anti-TLR2 antibody
treatment was significant at all concentrations; 10 and 50 ng/ml * p,0.01, 100 ng/ml ** p,0.005. Treatment of BV-2 cells with 100 ng/ml anti-TLR-2
antibody prior to LPS stimulation failed to inhibit miR-146a induction. The experiment was performed in triplicate and the average fold change is
shown. D. EOC 13.31 and BV-2 cells were stimulated with with 10
8 heat-killed Listeria monocytogenes (HKLM) cells/ml. RNA was collected at various
time-points over 72 hours and miR-146a expression measured by TaqManH qRT-PCR. Fold induction relative to unstimulated cells (US) is shown. The
experiment was performed in triplicate and the average fold change is shown.
doi:10.1371/journal.pone.0030832.g002
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PTPRC, SFRS1, SFRS5, SMAD3, C3 and DDX58. Other
groups of up-regulated genes included genes involved in cell cycle
progression, cell death, cellular movement and morphology. A
number of important transcriptional regulators PAX6, MDM2,
JAK2 and SMAS3 were increased, as were some caspases, CASP7
and CASP8, and the apoptotic regulator BCL2L1. Caspase-8 is
known to have non-apoptotic functions and has been shown to be
required for TLR signaling and in the regulation of NF-kB
function [36].
Similarly, over-expression of miR-146a was achieved by
transfection of a miRNA mimic and LPS stimulation was
performed 24 hours later, followed by transcriptional analysis at
8 and 24 hours. A significant number of genes were de-regulated
under these conditions, 22 (3 down-regulated, 19 up-regulated) at
8 hours post transfection and 977 (778 down-regulated, 199 up-
regulated) at 24 hours. At the 8 hour time-point the cells over-
expressing miR-146a share very similar transcriptional profiles
with mock-transfected, LPS stimulated cells. However, at the later
time-point of 24 hours post stimulation, significant changes in the
expression of multiple genes are observed relative to the controls.
A diagram depicting the expression data produced 24 hours post-
stimulation is provided in Figure 6A. Analysis of the biological
functions of those genes modulated by miR-146a expression
revealed primarily the down-regulation of immune response
effector genes in comparison to the mock-transfected, LPS
stimulated cells. Signaling pathways involving NF-kB, JNK and
MAPK are implicated in Figure 6B.
To confirm the down-regulation of immune effectors at the
protein level we used ELISAs to determine IL-6 and GM-CSF
(CSF2) levels upon TLR stimulation in miR-146 over-expressing
cells. Production of these cytokines was significantly reduced by
miR-146a over-expression upon TLR2 stimulation of EOC 13.31
cells versus cells transfected with a scrambled control RNA
(Figure 7). Highly significant (p,0.001) down-regulation of IL-6
and GM-CSF following miR-146a over-expression correlated well
with our genomic data. In addition, transfection of a miR-146a
anti-miR resulted in a small but significant up-regulation of IL-6 in
these cells, presumably correlating with a reduction of endogenous
miR-146a by anti-miR sequestration in EOC 13.31 cells. One up-
regulated cytokine coding gene was IL-10, a negative regulator of
cytokine production during the immune response; however, this
gene was expressed at very low levels based on the spot intensity
observed by microarray and we were unable to detect IL-10
expression by ELISA. Table 4 provides a summary list of some of
these inflammation-related genes that appear altered in response
to increased expression of miR-146a, in the process illustrating a
potential dampening effect of the transcriptional response to
stimulation.
Direct targets of miR-146a important in immune activation are
likely to be those found at the intersection of genes that are up-
regulated following knock-down and down-regulated after over-
expression, provided that they exhibit altered expression that is
detectable at the mRNA level. We found that 36 genes, out of a
total of 160 significantly de-regulated genes whose expression
followed this pattern, that were also bioinformatically predicted
targets of miR-146a using the TargetScan 5.1 program and IPA
software. These are listed in Table 5. The transcription regulator
SMAD3 was identified as a potential target of miR-146a in both
resting cells and those stimulated with LPS and has not been
described to be a target of miR-146a. In addition, NOS2, QK1
and BCL2L1 are also predicted from this study as being strong
candidates for targeting by miR-146a that have not previously
been described. They are also highly related based on potential
interactions identified using the IPA tool, potentially a co-
ordinately regulated gene set. Previously, TRAF6, IRAK1 and
IRAK2 have been identified and validated as putative targets of
miR-146a in macrophages [16,37]. These targets have been
shown to be regulated primarily at the protein level, and in
accordance they were not identified during this transcription based
Figure 3. EOC 13.31 cells were stimulated with 100 ng/ml semi-pure LPS and temporal changes in cytokine gene expression
relative to mock-treated control were measured by microarray analysis. MiR-146a expression relative to mock-treated control was
measured by TaqManH qRT-PCR and expression is shown as grey bars.
doi:10.1371/journal.pone.0030832.g003
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expression in miR-146a transfected and LPS stimulated cells
versus control was indeed observed in our work.
Discussion
Microglial cells, the brain’s resident immune effector cells,
respond to prion deposition by the conversion of a resting
phenotype into one that is ‘activated’. However, although they
take on an activated phenotype they synthesize fairly low levels of
pro-inflammatory cytokines; presumably as a defense mechanism
to prevent the severe pathology that can arise in host tissue as a
result of an acute inflammatory response induced by rampant
signaling in phagocytes. The specific stimuli and signaling
pathways that lead to this modulation of functions are as yet
unknown; however, it is evident that tight regulation exists in
activated microglia modulating their production of pro-inflamma-
tory cytokines although phenotypic changes are evident that are
indicative of phagocytic capability. It is yet to be determined
whether microglial activation reflects a direct response to prion
toxicity or a secondary response to clear cell debris following
neuronal damage and death. However, it is clear that phenotypic
changes in microglia are one of the earliest apparent alterations in
tissue pathology detectable during disease.
Firstly, we confirmed that miR-146a is over-expressed in the
brain’s of mice during scrapie infection and that this expression is,
most likely, highly enriched in cells of microglial origin based on
miRNA expression profiling of various brain-derived cell lines.
Nevertheless, it is also possible miR-146a is expressed at low levels
in other cell types. In subsequent studies using TaqManH qRT-
PCR assays we have found that miR-146a is expressed at low
levels in laser capture microdissected (LCM) neurons isolated from
mouse hippocampus (data not shown) and the expression and/or
induction of this miRNA in neurons is therefore a strong
possibility. Additionally, a number of miRNAs found to be up-
regulated in a recent study profiling glial cells in multiple sclerosis
brain lesions, as well as our previous study to determine
deregulated miRNAs in scrapie infection, were also identified to
be enriched in microglial cell lines in this study [18,38]. These
were miR-142-3p, miR-34a, and miR-223. Further work to
determine whether these miRNAs also play a role in the regulation
of innate immunity, NOS production or phagocytosis was beyond
the scope of the present study.
Initially, we attempted to use oligomeric recombinant PrP or
the neurotoxic peptide, PrP
106–126, to induce activation of miR-
146a induction in several microglial cell lines, however, this
proved to be unsuccessful, as we observed little to no activation of
this miRNA (data not shown). The limited transcriptional response
to prions in cultured microglia, and to a certain extent cultured
neuronal cells, is in stark contrast with the robust transcriptional
responses that is often obtained from whole brain tissue. This
discrepancy is very likely multi-factorial and contributing factors
include, but are certainly not limited to, lack of multiple cell types
and associated cell-to-cell signaling in in vitro culture, lack of
normal cellular functions under in vitro conditions, and also the
time required for disease progression, which is often months to
years in whole organism/animal. It is often speculated that the in
vivo transcriptional response likely represents the host’s response to
the process of neurodegeneration as much, if not more than, the
response specifically to prions, which may account for our inability
to detect a robust miR-146a induction in the cultured microglia.
Due to this limitation, we therefore used microarray analysis to
determine which microglial surface receptors are over-expressed in
the brains of an RML scrapie model of prion disease and therefore
likely to play a pertinent role in the activation state of microglia.
TLR2 appeared to be the most up-regulated and abundant
receptor in our model although other receptors including Fc
(FCGR1 and FCGR2) and complement receptors (ITGAM and
ITGAX) were also found to be over-expressed. Further investiga-
tion into whether stimulation of these receptors is involved in prion
pathobiology is warranted. Contrary to previous reports, we did
not find the scavenger receptors SCARB1, SCARB2 and AGER
to be up-regulated during disease [39]. Interestingly TLR2, and
TLR7 which was also up-regulated in our prion model, has also
been shown to display profoundly increased expression levels in
APP transgenic mice that accumulate amyloid deposits in their
brain [40]. Furthermore, an injection of amyloid into the
hippocampus provokes increased TLR2 expression [41]. It has
previously been reported that TLR4 is also increased in prion
models, although in our study the transcript coding for TLR4 was
below the level of detection. Further evidence that TLRs may be
important in the regulation of the microglial response in prion
Figure 4. Altering the expression of miR-146a in microglia. A.
MiR-146a over-expression as measured by TaqManH qRT-PCR in
microglia cells after 8, 24, and 48 hrs of treatment with 30 nM
(previously optimized, data not shown) of transfected pre-miR-146a in
comparison to 30 nM of transfected scrambled negative control miRNA.
An average fold change and standard deviation were measured from
triplicate experiments. B. MiR-146a knock-down as measured by
TaqManH qRT-PCR in microglia cells after 8, 24, and 48 hrs of treatment
with 50 nM (previously optimized, data not shown) of transfected anti-
miR-146a in comparison to 50 nM of transfected scrambled negative
control miRNA. An average fold change and standard deviation were
measured from triplicate experiments.
doi:10.1371/journal.pone.0030832.g004
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signaling, making them hyporesponsive to LPS, exhibit an
accelerated rate of prion disease [11]. This implies a protective
role for TLR stimulation of microglia during disease. In
Alzheimer’s disease, a pathology in which an oligomeric form of
beta amyloid (Ab) builds up in a similar fashion to PrP
Sc in prion
disease, phagocytosis of Ab by activated microglia is significantly
increased in the presence of ligands that activate TLRs [42–44].
Landreth and Reed-Geaghan (2009) have also shown that the
response of microglia to fibrillar Ab is reliant upon the expression
Figure 5. Analysis of genes dysregulated by over-expression, or knock-down of miR-146a in resting EOC 13.31 cells using either
miRNA mimics or anti-miRs. A. Venn diagram to show the intersection between genes down-regulated by miR-146a over-expression, up-
regulated on miR-146a knock-down and those targets bioinformatically predicted using the TargetScan 5.1 program and IPA software. B. Networks
showing the interactions between several predicted miR-146a target genes. Shaded grey are those genes also bioinformatically predicted using the
TargetScan 5.1 program and IPA software.
doi:10.1371/journal.pone.0030832.g005
Dysregulation of miR-146a and Microglial Function
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30832of TLR4, TLR2 and the co-receptor CD14 to activate
intracellular signaling [45]. Cells lacking these receptors could
not initiate a Src-Vav-Rac signaling cascade required to stimulate
phagocytosis of amyloid beta deposits [45].
TLR4 stimulation of the BV-2 microglial cell-line resulted in
activation and in the transcription of miR-146a, as did stimulation
with the TLR2 agonist HKLM. EOC 13.31 cells that lack a
functional TLR4 receptor could also be induced to over-express
miR-146a on stimulation with a TLR2-agonist. Our first finding
was that in contrast to the rapid and transient induction of
transcription of inflammatory mediators such as cytokines IL-6
and TNF, miR-146a expression follows alternate kinetics. MiR-
146a was induced at a slower rate, reaching a peak after 24 hours
that is maintained even at 48 and 72 hours post-stimulation; time-
points when cytokine expression levels have returned to base-line.
We hypothesize that miR-146a may be involved in a prolonged
dampening of the innate immune response following activation.
MiR-146a may also contribute to the establishment of a microglial
state primed in some way for response to repeated exposure to
immune activators, as has recently been suggested to occur in
macrophages [31].
To more fully understand the transcriptional response modu-
lated by miR-146a, we performed knock-down or over-expression
experiments on cells either in resting or TLR-stimulated state. We
sought to determine the full extent of changes elicited by miR-
146a, not just direct targets but also those transcripts that are
down-stream of the direct targets. Whole pathways may be down-
regulated, for example, if a receptor is a direct target.
Alternatively, up-regulated mRNAs may perhaps indicate that
the miRNA target is a negative regulator of transcription or of a
signaling pathway. Knock-down may produce the opposite effect
in some instances if basal levels of miRNAs are exerting a
regulatory effect.
A functional genomic analysis using over-expression and knock-
down of miR-146a in ‘resting’ EOC 13.31 cells or following
stimulation of TLR revealed significant alteration of numerous
transcripts. Notably, these included numerous genes important to
phagocyte function including genes involved in the inflammatory
response (the production of cytokines and prostaglandins) as well
as genes involved in phagocytosis including the cellular morpho-
logical changes that accompany activation and the oxidative burst.
It was interesting to observe the down-regulation of important
phagocytosis related genes such as IL-1B, iNOS and CYBA (part
of the NADPH oxidase complex which is the primary source of
reactive oxygen intermediates produced during oxidative burst) in
resting cells. In particular, IL-1B, a key mediator of the
inflammatory response, is both down-regulated following miR-
146a over-expression and up-regulated after knock-down. This
suggests that the basal level expression of IL-1B in microglia is
modulated, in part, by miR-146a.
Other significant alterations in expression include downstream
mediators of the pro-inflammatory transcription factor, nuclear
factor-kappa B (NF-kB) and the JAK-STAT signaling pathway
(Figure 4B). Previous studies have determined that miR-146a can
regulate NF-kB itself, as well as key genes downstream of NF-kB
[16]. MiR-146a is also transcribed by NF-kB and therefore may
operate as part of a feedback inhibitory regulatory-loop to
modulate inflammation by this transcription factor [46]. Validated
miR-146a targets include two genes that are important mediators
of TLR signaling [16]. These genes are IRAK1, which is in part
responsible for transcription of NF-kB in response to immune
stimulation, and TRAF6. The 39UTRs of these genes are
responsive to interaction with miR-146a, however, regulation
was shown to be at the level of translation; mRNA levels remained
unchanged. The mRNA levels of IRAK1 were similarly found to
be unchanged in our study, although we measured a small, but
significant, down-regulation of TRAF6 gene expression in EOC
13.31 cells transfected with a miR-146a mimic.
Expression of the complement factor H (CFH) gene was another
of those genes down-regulated on application of miR-146a mimic.
Interestingly, this gene has been shown to be targeted by miR-
146a and down-regulated in Alzheimer’s disease as well as in other
diseases such as Herpes simplex virus type1 infection [47,48]. It
Table 3. Analysis of genes dysregulated by over-expression,
or knock-down, in resting EOC 13.31 cells using either miR-
146a mimics or anti-miRs.
Symbol Entrez Gene Name
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
CACNB2 calcium channel, voltage-dependent, beta 2 subunit
CASK calcium/calmodulin-dependent serine protein kinase
CDC42ER2 CDC42 effector protein (Rho GTPase binding) 2
CDK7 cyclin-dependent kinase 7
CHRNA1 acetylcholine receptor subunit alpha-1-A
CPSF2 cleavage and polyadenylation specific factor 2
CYP2B6 E74-like factor 1 (ets domain transcription factor)
DNAH1 dynein, axonemal, heavy chain 1
EDEM2 ER degradation enhancer, mannosidase alpha-like 2
EPHA5 Eph receptor A5
GALM galactose mutarotase (aldose 1-epimerase)
GATA6 GATA binding protein 6
GFAP glial fibrillary acidic protein
GHSR growth hormone secretagogue receptor
GLI3 GLI family zinc finger 3
GRIA3 glutamate receptor, ionotrophic, AMPA
HIPK2 homeodomain interacting protein kinase 2
HLA-A major histocompatibility complex, class I, A
HLA-B major histocompatibility complex, class I, C
HLA-C major histocompatibility complex, class I, C
IL1B interleukin-1-beta
IRF6 interferon regulatory factor 6
KALRN kalirin, RhoGEF kinase
KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5
KDR kinase insert domain receptor
KLK10 kallikrein-related peptidase
MLLT4 myeloid/lymphoid or mixed-lineage leukemia
NRG1 neuregulin 1
NTRK2 neurotrophic tyrosine kinase, receptor, type 2
PARD6B par-6 (partitioning defective 6) homolog beta
RRBP1 ribosome binding protein 1 homolog
RYR3 ryanodine receptor 3
SMAD3 SMAD family member 3
TMSB4X thymosin-like 2
TUBA1C tubulin, alpha 1c
TYRP1 tyrosinase-related protein 1
Genes listed in bold are those that are bioinformatically predicted to be targets
of miR-146a using the TargetScan 5.1 program and IPA software.
doi:10.1371/journal.pone.0030832.t003
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was a highly significant group of ontologically related genes
involved in small RNA processing. These included TNRC6A and
TNRC6B, two important proteins found in P-bodies associated
with Argonaute [49]. This finding could potentially reflect a
function of miR-146a in the regulation of P-body function and
processing of miRNAs themselves, perhaps by relieving miR-146a
inhibition of a transcriptional repressor. An alternative explana-
tion is that this may reflect a non-specific cellular response to the
transfection of miRNA in the cell.
We hypothesized that miR-146a targets, that directly modulate
an immune response, would likely only be apparent following an
Figure 6. Analysis of genes dysregulated upon over-expression, or knock-down, of miR-146a in stimulated EOC 13.31 cells using
either miRNA mimics or anti-miRs. A. Venn diagram to show the intersection between genes down-regulated in LPS stimulated EOC 13.31 cells
by miR-146a over-expression, and those up-regulated upon miR-146a knock-down. Also shown are those targets bioinformatically predicted using
the TargetScan 5.1 program and IPA software. B. Schematic showing alterations in expression in key inflammatory response-related genes in LPS
stimulated EOC 13.31 cells following miR-146a over-expression. Colored green are those down-regulated genes, colored red are up-regulated genes,
while those highlighted in blue are bioinformatically predicted targets of miR-146a using the TargetScan 5.1 program and IPA software.
doi:10.1371/journal.pone.0030832.g006
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regulated genes were evident upon the over-expression or knock-
down of miR-146a following TLR stimulation. Most notable was
the expanded list of cytokines and inflammatory mediators whose
transcripts were significantly decreased in comparison to the levels
measured in mock-transfected, stimulated, microglial cells. The
primary effector mechanism of innate-immunity is the generation
of acute and chronic inflammatory responses notably through
regulation of cytokines IL-1B and IL-18. Interestingly, IL-1B
appeared to be tightly regulated by miR-146a; its expression is
decreased following transfection of the miR-146a mimic and
increased following knock-down with an anti-miR in both resting
and TLR-stimulated cells. Knock-down also appeared to relieve
expression of the IL-18 receptor; IL-18 being another key
mediator of the inflammatory response to tissue damage.
Conversely, we found a small number of genes to increase in
expression upon transfection of a miR-146a mimic. One of these
was IL-10, an anti-inflammatory cytokine that can down-regulate
the expression of cytokines, MHC class II molecules, and co-
stimulatory molecules on macrophages, and has been found to be
up-regulated in human patients with CJD [50]. Additionally, it can
block NF-kB activity, and is involved in the regulation of the JAK-
STAT signaling pathway. The ability of IL-10 to decrease the
production of pro-inflammatory cytokines has been suggested as a
potential protective role in neurodegenerative diseases. Other anti-
inflammatory cytokines exist, such as IL-4, IL-13 or TGF-b,
however, no relative change in the expression levels of these
cytokines was observed in LPS treated microglia following over-
expression of miR-146a. However, a TGF-b activated transcrip-
tion factor SMAD3 was identified as a potential miR-146a target
in both resting and LPS stimulated cells, suggesting a possible role
for SMAD3 in microglial activation. SMAD3 knock-out mice
exhibit alterations in many aspects of glial function, including
altered scar formation and immune response to injury [51]. Fewer
Figure 7. EOC 13.31 cells were transfected with 30 nM of miR-146a mimic or anti-miR and 16 hrs later stimulated with 10 ng/ml
LPS. At 24 hours post LPS stimulation, culture supernatant was collected and the levels of IL-6 and GM-CSF (coded for by the gene CSF2) were
determined by ELISA; significance: ** p,0.001, * p,0.01.
doi:10.1371/journal.pone.0030832.g007
Table 4. Inflammation-related genes that are altered in response to increased expression of miR-146a in LPS stimulated EOC 13.31
cells.
ADM CD44 CXCL10 FOS IFNA5 IRGM MX2 SLC7A2 TRIM21
AP3D1 CD69 CXCL11 FPR2 IFNB1 ITGAM MYC SLPI TRPC2
BCL2L1 CEBPB CXCL3 GBP2 IKBKE KITLG NCF1 SMAD3 TSLP
CASP3 CEBPG CXCL6 GIMAP5 IL10 LCN2 NFATC3 STAT1 VCAM1
CBLB CHUK CXCL9 HP IL12B LCP2 NFKB1 STAT2 ZCCHC11
CCL20 CIITA DLG1 ICOSLG IL15 LTA NOS2 TGFBR3
CCL3 CSF2 DOCK2 IER3 IL16 MALT1 PDCD1 TLR2
CCL5 CSF3 DPP8 IFI44L IL1A MAP4K2 PF4 TLR3
CD274 CSK ERAP1 IFI47 IL1B MGST1 PTGS2 TNF
CD28 CX3CL1 EREG IFIH1 IL1RN MSH2 RNASEL TNFSF10
CD40 CXCL1 FAS IFNA16 IL6 MX1 S100A10 TP53
Down-regulated genes are in bold italics, up-regulated genes are in plain type.
doi:10.1371/journal.pone.0030832.t004
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GFAP-positive cells were reported around lesions in Smad3 null
mice brains. Therefore, down-regulation of SMAD3 by miR-146a
expression could well be an important mechanism to modulate
immune response and glial migration.
Given that TLR2 is extremely abundant and highly up-
regulated upon prion infection, we hypothesize that signaling
through this TLR plays a role during disease. MyD88 is the main
adaptor protein implicated in TLR signaling and is considered
essential for the induction of inflammatory cytokines triggered by
most TLRs, including TLR2. Nevertheless, the study determined
by Prinz et al. (2003) showed that MyD88 knock-out mice were
readily infectable with scrapie and did not show any significant
alteration in the time-course or pathology of the disease [12]. This
data implies that TLR2-signaling is not essential to the disease
process and that our model may not mimic processes that occur
during disease. However, effector molecules downstream of
multiple cell surface receptors, including TLR2 (and TLR4)
signals, are similar and the action of miR-146a to modulate the
innate immune response and microglial activation in these model
systems is likely to be indicative, despite the original upstream
signal. In addition, recent studies have shown that TLR2
stimulation is indeed capable of eliciting a MyD88- and TRIF-
independent inflammatory cytokine response [52]. Some evidence
also exists suggesting that this response is independent of
phagocytic clearance pathways that appear to be MyD88
dependent [53]. Interestingly, in a mouse model of Alzheimer’s
disease, MyD88 deficient and APP over-expressing mice had an
accelerated disease process pointing to a role for MyD88 in
clearance of amyloid [54]. It has also been reported by others that
TLR 2, 4, and 9 signaling modulates phacogytosis and clearance
of neurotoxic amyloid deposition in neurodegenerative diseases,
perhaps by MyD88 independent signaling pathways [43,55].
Those genes that are involved in phagocytosis and morphological
changes that are altered in response to miR-146a over-expression
may therefore be important to these processes. Studies also link a
reduction in TLR2 expression with an increase in phagocytosis,
implying an inverse relation between TLR2 expression and
phagocytic activity. In terms of prion disease this suggests the
considerable increase in expression of TLR2 observed at clinical
stages of prion disease could be indicative of the accumulation of
microglia that are not in an activation state that is optimal for
phagocytosis. This could therefore contribute to defective clearing
of debris and prion accumulation during later stages of disease.
Investigation into whether TLR2 signaling is indeed important in
prion disease pathology, and the identification of signaling
pathways important in microglial activation independent of
MyD88, warrants further investigation.
Ultimately, therapeutic modulation of the immune system in the
brain, perhaps by anti-miRNA strategies to repress the effects of
up-regulated miRNAs, is a goal for treatment of progressive
neurodegeneration. At a simplistic level knocking-down micro-
RNAs such as miR-146a, whose increased expression correlates
with disease progression, may present a treatment strategy. On the
other hand, this up-regulation may, in fact, be providing
protection from potentially harmful immune stimulation and
knock-down may be counter productive. We initially hypothesized
that given the immunomodulatory role ascribed to miR-146a in
macrophages, the up-regulation of miR-146a in scrapie infected
brain may reflect a role in keeping the pro-inflammatory response
of microglia to prion replication and degeneration ‘‘in-check’’ and
be beneficial to the course of disease. We show here that miR-146a
appears to have an overarching role in microglial function
Figure 8. Not only are genes involved in cytokine and other
aspects of the inflammatory response regulated by its expression,
but we found in this study that genes involved in morphological
changes that accompany activation, chemotaxis and oxidative
burst-related genes may also be targets for either direct or indirect
miR-146a regulation. Therefore, altering miR-146a levels in a
prolonged therapeutic attack against neurodegenerative processes
may have unforeseen consequences such as altering the phagocytic
potential of microglia to remove toxic protein inclusions. In
summary antisense-miRNA therapeutic strategies offer huge
promise over siRNA strategies because of the potential to affect
the regulation of multiple disease-related genes simultaneously.
However, studies such as this, to define the exact sphere of
influence of a miRNA targeting multiple gene networks are
essential to assessing their ultimate therapeutic potential.
Table 5. Analysis of genes dysregulated by over-expression,
or knock-down, of miR-146a in LPS stimulated EOC 13.31 cells
using either miRNA mimics or anti-miRs.
Symbol Entrez Gene Name
AMPD3 adenosine monophosphate deaminase (isoform E)
ARCN1 archain 1
BCL2L1 BCL2-like 1
CSDE1 cold shock domain containing E1, RNA-binding
CSTF2 cleavage stimulation factor, 39 pre-RNA, subunit 2, 64 kDa
DARS aspartyl-tRNA synthetase
DHRS9 dehydrogenase/reductase (SDR family) member 9
ELF1 E74-like factor 1 (ets domain transcription factor)
FAM107B family with sequence similarity 107, member B
FUBP1 far upstream element (FUSE) binding protein 1
HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
IFIT2 interferon-induced protein with tetratricopeptide repeats 2
IRS1 insulin receptor substrate 1
MED1 mediator complex subunit 1
NOS2 nitric oxide synthase 2, inducible
PCTK2 PCTAIRE protein kinase 2
POGK pogo transposable element with KRAB domain
PSME4 proteasome (prosome, macropain) activator subunit 4
QKI quaking homolog, KH domain RNA binding
QSER1 glutamine and serine rich 1
RAB8B RAB8B, member RAS oncogene family
RAI14 retinoic acid induced 14
SEC23A Sec23 homolog A
SH3BGRL SH3 domain binding glutamic acid-rich protein like
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member
3
SMAD3 SMAD family member 3
SOX10 SRY (sex determining region Y)-box 10
TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 31 kDa
TFCP2L1 transcription factor CP2-like 1
UBE2K ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
Genes listed are those that are bioinformatically predicted to be targets of miR-
146a using the TargetScan 5.1 program and IPA software.
doi:10.1371/journal.pone.0030832.t005
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